Research Investments in Global Health: A Systematic Analysis of UK Infectious Disease Research Funding and Global Health Metrics, 1997-2013

被引:22
|
作者
Head, Michael G. [1 ,2 ]
Fitchett, Joseph R. [3 ,4 ]
Nageshwaran, Vaitehi [5 ]
Kumari, Nina [5 ]
Hayward, Andrew [1 ]
Atun, Rifat [4 ]
机构
[1] UCL, Farr Inst Hlth Informat, 222 Euston Rd, London NW1 2DA, England
[2] Univ Southampton, Fac Med, Acad Unit Clin & Expt Sci, Southampton SO9 5NH, Hants, England
[3] London Sch Hyg & Trop Med, Keppel St, London WC1, England
[4] Harvard Univ, Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA
[5] Univ London Imperial Coll Sci Technol & Med, Sch Med, London, England
来源
EBIOMEDICINE | 2016年 / 3卷
基金
英国生物技术与生命科学研究理事会; 英国医学研究理事会; 英国惠康基金;
关键词
Infectious disease; Research investment; Disease burden; Global health; Funding; BURDEN;
D O I
10.1016/j.ebiom.2015.12.016
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Infectious diseases account for a significant global burden of disease and substantial investment in research and development. This paper presents a systematic assessment of research investments awarded to UK institutions and global health metrics assessing disease burden. Methods: We systematically sourced research funding data awarded from public and philanthropic organisations between 1997 and 2013. We screened awards for relevance to infection and categorised data by type of science, disease area and specific pathogen. Investments were compared with mortality, disability-adjusted life years (DALYs) and years lived with disability (YLD) across three time points. Findings: Between 1997-2013, there were 7398 awards with a total investment of 3.7 pound billion. An increase in research funding across 2011-2013 was observed for most disease areas, with notable exceptions being sexually transmitted infections and sepsis research where funding decreased. Most funding remains for pre-clinical research (2.2 pound billion, 59.4%). Relative to global mortality, DALYs and YLDs, acute hepatitis C, leishmaniasis and African trypanosomiasis received comparatively high levels of funding. Pneumonia, shigellosis, pertussis, cholera and syphilis were poorly funded across all health metrics. Tuberculosis (TB) consistently attracts relatively less funding than HIV and malaria. Interpretation: Most infections have received increases in research investment, alongside decreases in global burden of disease in 2013. The UK demonstrates research strengths in some neglected tropical diseases such as African trypanosomiasis and leishmaniasis, but syphilis, cholera, shigellosis and pneumonia remain poorly funded relative to their global burden. Acute hepatitis C appears well funded but the figures do not adequately take into account projected future chronic burdens for this condition. These findings can help to inform global policymakers on resource allocation for research investment. (C) 2015 The Authors. Published by Elsevier B.V.
引用
收藏
页码:180 / 190
页数:11
相关论文
共 50 条
  • [1] Research investments for UK infectious disease research 1997-2013: A systematic analysis of awards to UK institutions alongside national burden of disease
    Head, Michael G.
    Brown, Rebecca J.
    Clarke, Stuart C.
    JOURNAL OF INFECTION, 2018, 76 (01) : 11 - 19
  • [2] Investments in sexually transmitted infection research, 1997-2013: a systematic analysis of funding awarded to UK institutions
    Head, Michael G.
    Fitchett, Joseph R.
    Cassell, Jackie A.
    Atun, Rifat
    JOURNAL OF GLOBAL HEALTH, 2015, 5 (02) : 89 - 97
  • [3] Funding Infectious Disease Research: A Systematic Analysis of UK Research Investments by Funders 1997-2010
    Fitchett, Joseph R.
    Head, Michael G.
    Cooke, Mary K.
    Wurie, Fatima B.
    Atun, Rifat
    PLOS ONE, 2014, 9 (08):
  • [4] Differences in research funding for women scientists: a systematic comparison of UK investments in global infectious disease research during 1997-2010
    Head, Michael G.
    Fitchett, Joseph R.
    Cooke, Mary K.
    Wurie, Fatima B.
    Atun, Rifat
    BMJ OPEN, 2013, 3 (12):
  • [5] Funding infectious disease research: A systematic analysis of UK investments by funders 1997-2010
    Fitchett, J. R.
    Head, M.
    Atun, R.
    Cooke, M.
    Wurie, F.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2014, 21 : 396 - 396
  • [6] Investments in respiratory infectious disease research 1997-2010: a systematic analysis of UK funding
    Head, Michael G.
    Fitchett, Joseph R.
    Cooke, Mary K.
    Wurie, Fatima B.
    Hayward, Andrew C.
    Lipman, Marc C.
    Atun, Rifat
    BMJ OPEN, 2014, 4 (03):
  • [7] Mapping pneumonia research: A systematic analysis of UK investments and published outputs 1997-2013
    Head, Michael G.
    Fitchett, Joseph R.
    Newell, Marie-Louise
    Scott, J. Anthony G.
    Harris, Jennifer N.
    Clarke, Stuart C.
    Atun, Rifat
    EBIOMEDICINE, 2015, 2 (09): : 1193 - 1199
  • [8] Infectious disease research investments: Systematic analysis of immunology and vaccine research funding in the UK
    Fitchett, Joseph R.
    Head, Michael G.
    Atun, Rifat
    VACCINE, 2013, 31 (50) : 5930 - 5933
  • [9] UK investments in global infectious disease research 1997-2010: a case study
    Head, Michael G.
    Fitchett, Joseph R.
    Cooke, Mary K.
    Wurie, Fatima B.
    Hayward, Andrew C.
    Atun, Rifat
    LANCET INFECTIOUS DISEASES, 2013, 13 (01): : 55 - 64
  • [10] Systematic analysis of global health research funding in Canada, 2000–2016
    Steven J. Hoffman
    Elliot Gunn
    Susan Rogers Van Katwyk
    Stephanie Nixon
    Canadian Journal of Public Health, 2020, 111 : 80 - 95